Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Religion

Thimerosal

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

MENINGOCOCCAL VACCINE

Recommendation of the ACIP for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease MMWR 2011;60(40):1391. (10-14-11)

Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease - ACIP, 2011   MMWR;60(30):1018.   (8-5-11)

Updated Recommendations for Use of Meningococcal Conjugate Vaccines -- ACIP, 2010  MMWR;60(03):72. (1-28-11)

Menveo, Novartis's quadrivalent meningococcal conjugate vaccine, approved by US FDA for active immunization of individuals 11 through 55 years of age to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C,Y and W-135. (2-19-10) package insert [PI updated 3/11]

Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM... A study published by Gasparini R et al in Clinical Vaccine Immunology indicates that the investigational MenACWY-CRM vaccine is well tolerated and immunogenic, and can be co-administered with Tdap in adolescents and young adults. (2-24-10) PubMed abstract

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Halperin et al report their findings of a phase II clinical trial in a population of infants and toddlers in the European Journal of Clinical Microbiology and Infectious Disease. (03-2010) PubMed abstract.

Update on Guillain Barre Syndrome following meningococcal conjugate vaccine (Menactra): No change in recommendations for use of the vaccine.  The FDA and CDC have updated their information on Guillain Barre Syndrom (GBS) after meningococcal conjugate vaccine [link to MMWR]. GBS is a neurological disorder associated with a progressive paralysis over several days to weeks. Most people with GBS recover over a period of many weeks of months. The evidence generated by CDC and FDA suggests that there could be an increased risk of GBS of about one in one million following Menactrra in adolescents, but additional studies are needed to clearly answer this question.
Since the known risk of severe complications from meningococcal infections is high in this age group, the CDC has not altered the recommendations for routine use for adolescents, college freshmen living in dorms and others at high risk for the disease.
CDC has provided detailed information (11-01-06)

Guillain-Barré Syndrome Among Recipients of Menactra® Meningococcal Conjugate Vaccine - United States, June-July 2005. MMWR 2005;54(Dispatch);1-3. - Descriptions and details about the 5 cases of GBS after receipt of meningococcal vaccine. (10- 2005)

FDA/CDC issue an alert on meningococcal vaccine following 5 reported cases of Guillain Barre Syndrome after receipt of Menactra. (10-2005)

This page was last updated on February 12, 2014

© 2014 Institute for Vaccine Safety